We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

75 hedge funds and large institutions have $264M invested in BioCryst Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $6.94M | Put options by funds: $3.7M

61% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 18

21% more capital invested

Capital invested by funds: $217M → $264M (+$46.2M)

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 73 → 75 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
75
Holders Change
+2
Holders Change %
+2.74%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
29
Reduced
18
Closed
13
Calls
$6.94M
Puts
$3.7M
Net Calls
+$3.24M
Net Calls Change
+$1.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.7M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$10.2M
4
BFA
BlackRock Fund Advisors
California
+$4.35M
5
Morgan Stanley
Morgan Stanley
New York
+$2.9M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$9.48M
2
DM
Deerfield Management
New York
-$4.84M
3
TC
TFS Capital
Pennsylvania
-$4.53M
4
BIM
Bogle Investment Management
Massachusetts
-$2.81M
5
VM
VHCP Management
New York
-$2.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
51
Deutsche Bank
Germany
$157K +$127K +20,073 +2,868%
UBS AM
52
UBS AM
Illinois
$156K +$130K +20,500 New
Commonwealth Equity Services
53
Commonwealth Equity Services
Massachusetts
$145K -$1.58K -250 -1%
GC
54
Guggenheim Capital
Illinois
$134K +$6.62K +1,045 +6%
Invesco
55
Invesco
Georgia
$125K +$4.12K +650 +4%
DTL
56
Dynamic Technology Lab
Singapore
$120K +$32.1K +5,070 +47%
Comerica Bank
57
Comerica Bank
Texas
$103K -$85.5K -13,500 -50%
SI
58
SII Investments
Wisconsin
$100K -$633 -100 -0.8%
JIC
59
Joel Isaacson & Co
New York
$91K – – –
Janney Montgomery Scott
60
Janney Montgomery Scott
Pennsylvania
$85.5K +$71.2K +11,250 New
LWM
61
Lyons Wealth Management
Florida
$84K +$6.33K +1,000 +10%
ID
62
Integral Derivatives
New York
$81K +$67.8K +10,709 New
BA
63
BlackRock Advisors
Delaware
$75K +$7.76K +1,226 +14%
ASN
64
Advisory Services Network
Georgia
$59K +$49K +7,732 New
Citigroup
65
Citigroup
New York
$50K +$28.7K +4,527 +222%
AIG
66
American International Group
New York
$26.6K – – –
Teacher Retirement System of Texas
67
Teacher Retirement System of Texas
Texas
$12K +$10.3K +1,633 New
LTFS
68
Ladenburg Thalmann Financial Services
Florida
$8K – – –
Bank of Montreal
69
Bank of Montreal
Ontario, Canada
$8K +$6.33K +1,000 New
TRCT
70
Tower Research Capital (TRC)
New York
$6K -$94.1K -14,860 -95%
Creative Planning
71
Creative Planning
Kansas
$6K – – –
WA
72
WFG Advisors
Texas
$5K – – –
Dimensional Fund Advisors
73
Dimensional Fund Advisors
Texas
$3K – – –
OC
74
Oakworth Capital
Alabama
$1K +$950 +150 New
Manulife (Manufacturers Life Insurance)
75
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$12 +$133 +21 +1%
1 2
3
4

BCRX Hedge Fund Activity: Q4 2013 in Review

75 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2013, worth a combined $264M — up 21% from $217M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BCRX positions and 13 closed out — a net gain of 2 holders — while 29 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $16.3M. The largest seller was RA Capital Management, cutting an estimated $9.48M.

  • 75 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2013, up from 73 in Q3 2013.
  • Funds reported $264M of BioCryst Pharmaceuticals stock for Q4 2013, up 21% quarter-over-quarter.
  • 15 funds opened new BioCryst Pharmaceuticals positions in Q4 2013 and 13 closed out, a net change of +2 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $16.3M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2013 was RA Capital Management, an estimated $9.48M sold.

Based on aggregated 13F filings for Q4 2013.